After reviewing 124 published studies, a federal team has concluded that there is no evidence to support the clinical use of stereotactic body radiation therapy (SBRT) over other radiation therapies.
The authors of the Agency for Healthcare Research and Quality (AHRQ) Technical Brief on SBRT (available here) found limited research comparing the safety and efficacy of this technique with other forms of external-beam radiation therapy.
Most studies addressed tumors of the lung or thorax; fewer than 10 studies each were found for tumors of the prostate, kidney, pancreas, liver, colon, uterus, pelvis, or sacrum.
Enjoying our content?
Thanks for visiting Renal & Urology News. We hope you’re enjoying the latest clinical news, full-length features, case studies, and more.
You’ve viewed {{metering-count}} of {{metering-total}} articles this month. If you wish to read unlimited content, please log in or register below. Registration is free.
{{login-button}} {{register-button}}
Log in to continue reading this article.
Don’t miss out on today’s top content on Renal & Urology News. Register for free and gain unlimited access to:
- Clinical News, with personalized daily picks for you
- Case Studies
- Conference Coverage
- Full-Length Features
- Drug Monographs
- And More
{{login-button}} {{register-button}}
Want to read more?
Please login or register first to view this content.